The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on August 1, 2023. The analyst firm set a price target for $8.00 expecting TNXP to rise to within 12 months (a possible 1045.31% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $18.00 to $8.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.70, which is out of the analyst’s predicted range.

The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on August 1, 2023. The analyst firm set a price target for $8.00 expecting TNXP to rise to within 12 months (a possible 1045.31% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $18.00 to $8.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.70, which is out of the analyst’s predicted range.

The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on August 1, 2023. The analyst firm set a price target for $8.00 expecting TNXP to rise to within 12 months (a possible 1045.31% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $18.00 to $8.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.70, which is out of the analyst’s predicted range.

The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on August 1, 2023. The analyst firm set a price target for $8.00 expecting TNXP to rise to within 12 months (a possible 1045.31% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $18.00 to $8.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.70, which is out of the analyst’s predicted range.

The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on August 1, 2023. The analyst firm set a price target for $8.00 expecting TNXP to rise to within 12 months (a possible 1045.31% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $18.00 to $8.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.70, which is out of the analyst’s predicted range.

The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on August 1, 2023. The analyst firm set a price target for $8.00 expecting TNXP to rise to within 12 months (a possible 1045.31% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $18.00 to $8.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.70, which is out of the analyst’s predicted range.

The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on August 1, 2023. The analyst firm set a price target for $8.00 expecting TNXP to rise to within 12 months (a possible 1045.31% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $18.00 to $8.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.70, which is out of the analyst’s predicted range.

The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on August 1, 2023. The analyst firm set a price target for $8.00 expecting TNXP to rise to within 12 months (a possible 1045.31% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $18.00 to $8.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.70, which is out of the analyst’s predicted range.